+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06833229

Study to Use 18FDG PET-CT Scans for Early Prediction of Immunotherapy Effectiveness With or Without Chemotherapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Led by Centre Antoine Lacassagne · Updated on 2026-05-29

200

Participants Needed

1

Research Sites

139 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of 18FDG PET scans to improve early detection of treatment response in patients with locally advanced or metastatic non-small cell lung cancer NSCLC who are treated with immunotherapy, with or without chemotherapy. This prospective observational pilot study aims to identify metabolic biomarkers on PET scans that may better predict tumor response compared to current standards. The study is sponsored by Centre Antoine Lacassagne and focuses on patients receiving certain immunotherapy drugs such as nivolumab, pembrolizumab, atezolizumab, durvalumab, or avelumab, sometimes combined with chemotherapy agents like carboplatin or cisplatin. Participants will undergo PET scans within 28 days before starting immunotherapy, then again at 6 weeks and 12 weeks during follow-up. These scans assess various metabolic parameters including changes in maximum standardized uptake value, total lesion glycolysis, appearance of new visceral lesions, and tumor response based on adapted PERCIST criteria for immunotherapy. The study also explores the use of deep-learning algorithms to classify patients as responders or non-responders to immunotherapy. Throughout the study, researchers will monitor metabolic changes on PET imaging to distinguish true tumor progression from pseudo-progression caused by inflammation. They will evaluate overall survival at 12, 24, and 36 months and assess outcomes related to oligometastatic progression and targeted irradiation. Patient data and PET scan results will be used to refine predictive models. Participation involves multiple PET scans and clinical follow-up over a period extending up to 36 months.

CONDITIONS

Brief Title

Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma

Research Team

S

Study Coordinator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here